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duced allograft survival and often experience prolonged waiting times prior to transplantation. Xenotransplantation, using genetically modified porcine organs, offers a unique source of donor organs for these highly sensitized patients if the anti-HLA antibody, which places the allograft at risk, does not also enhance anti-pig antibody reactivity responsible for xenograft rejection. Recent improvements in xenotransplantation efficacy have occurred due to improved immune suppression, identification of additional xenogeneic glycans, and continued improvements in donor pig genetic modification. Genetically engineered pig cells, devoid of the known xenogeneic glycans, minimize human antibody reactivity in 90% of human serum samples.
For waitlisted patients, early comparisons of patient PRA and anti-pig antibody reactivity found no correlation suggesting that patients with high PRA levels were not at increased risk of xenograft rejection. Subsequent studies have found that some, but not all, highly sensitized patients express anti-HLA class I antibody which cross-reacts with swine leukocyte antigen (SLA) class I proteins. Recent detailed antigen-specific analysis suggests that porcine-specific anti-SLA antibody from sensitized patients binds cross-reactive groups present in a limited subset of HLA antigens. This suggests that using modern genetic methods, a program to eliminate specific SLA alleles through donor genetic engineering or stringent donor selection is possible to minimize recipient antibody reactivity even for highly sensitized individuals. graft survival. 5, 6 The efficacy of preclinical xenotransplantation has recently improved with heterotopic pig-to-nonhuman primate (NHP) cardiac xenotransplantation [7] [8] [9] [10] now measured in years, encouraging early success in orthotopic cardiac transplantation [11] [12] [13] 
| S TR ATEG IE S FOR DE TEC TING HL A CROSS-RE AC TIVIT Y FOR XENOTR ANS PL ANTATION
Xenograft rejection is recognized as an overwhelmingly antibody driven process due to the very high level of anti-pig antibodies naturally present in human serum. The bulk of these antibodies are not directed to swine SLA but bind to the major xenogeneic glycan galactose alpha 1,3 galactose (αGal). 23 With the advent of pigs engineered with a GGTA-1 mutation, 24, 25 which eliminates αGal expression (GTKO), the impact of other antibodies directed to non-Gal antigen including SLA-I has become more apparent. 16, [26] [27] [28] There have been a limited number of studies designed to determine whether sensitization to HLA results in enhanced antibody reactivity to pig cells. 16, [29] [30] [31] [32] [33] [34] [35] [36] [37] These studies have been performed over a 20-year period and as such span a range of technological developments both for defining allo-sensitization and in technologies to detect xenoreactive antibody. In this review, the studies are presented as four basic research strategies based on the use of whole serum (type I), anti-Gal depleted serum (Type II) and anti-Gal and anti-Class I depleted serum (type III). The fourth study type largely used whole human serum but measured patient antibody reactivity to genetically modified porcine cells lacking the three known xenogeneic glycans (αGal, Neu5Gc modified glycans and SDa) with and without deletion of SLA-I genes.
| Type I studies
The earliest study 29 36 A recent study using cells from GTKO and GTKO/CMAHKO pigs expressing human CD46 also failed to find enhanced antibody reactivity in 10 highly sensitized wait listed serum samples. 37 Collectively these studies concluded that patients with high PRA sera do not necessarily produce correspondingly high titer of anti-pig antibody or a high levels of anti-pig cytotoxicity.
Thus, allo-sensitized patients would not be at greater risk of xenograft rejection. When allo-sensitized waitlisted patient serum is progressively absorbed with RBC and porcine platelets to deplete both anti-Gal and anti-SLA-I, it is evident that the residual αGal-independent antibody reactivity present in some highly sensitized patients reacts with swine SLA. Naziruddin et al 30 demonstrated that affinitypurified anti-Gal antibody binding to pig PBMNCs was effectively blocked by saturating levels of the αGal-specific lectin GSIB-4 but that antibody reactivity to pig PBMNCs in patients with medium to high PRA was αGal independent. This antibody reactivity was also 
| Type II and III studies

| Type IV studies
The most recent studies are based on a series of genetically modi- These studies confirm earlier reports that some, but not all, highly sensitized patient serum contains SLA-I-reactive antibody.
Importantly, these latest studies identify for the first time the MHC cross-reactive groups present on swine SLA-I making possible further genetic modification or selection to eliminate these alleles and minimize antibody reactivity even for highly sensitized patients.
| CON CLUS IONS
The prospects for clinical xenotransplantation have improved significantly due to recent increases in preclinical nonhuman primate xenograft survival. While the ideal donor organ is not universally defined and may be different for different organs, it seems likely that donor organs with minimal antigenicity (GGTA1/CMAH/ B4GALNT2) which minimize human antibody reactivity will make a prominent contribution. Additional genetic modifications to regulate complement and coagulation may also be used, but inclusion of these human transgenes should not affect antibody reactivity or tissue antigenicity. For most human sera and waitlisted patients with zero to moderate HLA sensitization, there appears to be minimal antibody reactivity to these triple knockout pig cells suggesting that future clinical xenotransplantation will be broadly applicable to most patients. Highly sensitized patients (PRA >80%) can produce antibody which cross-reacts with swine SLA-I, but this is not an obligate condition. Whether the SLA-I cross-reactive antibody in highly sensitized patients has immediate impact on xenograft survival will depend on the antibody titer, affinity and level of porcine SLA-I expression. Since recent studies suggest that cross-reactive anti-HLA antibody is directed to a limited set of HLA antigens, modern genetic screening and modification methods may be used to select for pigs with minimal antibody reactivity even for highly sensitized patients.
Patient cross-matching is a corner stone of successful allotransplantation and will undoubtedly play no less of a role in future clinical xenotransplantation.
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